AceLink Therapeutics, Inc., a clinical-stage biotech company developing next-generation oral substrate reduction therapies (SRTs), presented interim d ...
Fulcrum Therapeutics' promising treatment for Sickle Cell Disease and their strong financial position, despite setbacks.
Discover the latest developments in potential ALS treatments with COYA-302 and COYA-303, set to impact the $1.33 billion ...
Within the open-label basket trial, patients with two copies of one of two high-risk APOL1 gene variants will receive MZE829.
Ac-SSO110 has now received FDA orphan drug designation and investigational new drug application clearance for the treatment ...
Maze Therapeutics, Inc. (NASDAQ: MAZE), a clinical-stage biopharmaceutical company with a market capitalization of $569 million, has dosed the first patient in its Phase 2 HORIZON Study of MZE829, ...
The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and ...
Maze Therapeutics (MAZE) announced the first patient has been dosed in the company’s Phase 2 clinical trial, the HORIZON Study, of MZE829 in ...
MSD began worldwide recruitment for the trial and subjects are currently being enrolled. In the randomised trial, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback